1. ALLA AKTIER
  2. NYHETER
  3. NANOLOGICA

Nanologica

Nyheter Nanologica Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

EVENT AT NANOLOGICA'S PREMISES – NO DAMAGE TO PERSONNEL OR INSTRUMENTS

Over the weekend, a minor explosion occurred in an oven at a company that shares an office and laboratory corridor with Nanologica. The sprinkler system was activated automatically, and water was spread throughout the premises. No one has been injured and Nanologica's equipment is unharmed.

The initial assessment shows that none of Nanologica's instruments or other equipment has been damaged, as water has only spread to Nanologica's premises along the floor. The incident is under control and an investigation is ongoing to determine the exact cause.

Nanologica's large-scale production of silica is unaffected by the incident and measures are being taken to ensure that other work can continue with minimal impact.

For further information, please contact
Johanna Westerberg
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds. The Group is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Attachments
EVENT AT NANOLOGICA'S PREMISES – NO DAMAGE TO PERSONNEL OR INSTRUMENTS

Datum 2026-03-29, kl 22:08
Källa MFN
Bifogade filer
EVENT AT NANOLOGICA'S PREMISES – NO DAMAGE TO PERSONNEL OR INSTRUMENTS